SYNC bought 140K out of 350K traded |
Yes good bounce, means institutions are buying. |
Perhaps I won't be getting that avg, but not complaining :) |
Needs to hold down here really, otherwise it's all-time lows and then "who knows".
But I do like a cheap share, particularly one ADVFN'ers seem to have gone quiet on.
SYNC still got lots of cash, and Autolus, and most else is in for very little. But needs another sentiment turn on AUTL really. |
What a dog this is, how long can it go, may be tempted to buy and dump again. |
Autolus seems unable to keep its pants up for long. But SYNC still seems cheap to me, even if sometimes seems the only thing supporting it is the perma-buy back.
Edit - bought back in today. My buys having zero effect on the price, so a good chance I'll be averaging lower, but cheap is cheap. |
Looking better here......... |
Autolus looking promising. |
Desperate stuff. |
Share buy back seems to have stopped the drop for now. |
Syncona is in serious decline because of bad management, the issue must be addressed and quickly. |
Another round of selling coming, management charges urgently required. |
I made a small amount of money out of Sync several years ago.
Just having another look again given the bombed out share price
All of these sort of businesses have been hard hit by the rise in interest rates producing a double whammy of increased funding costs for portfolio companies and less opportunity to get an ipo away.
Having said that a point is reached when sentiment is too negative and I think we are nearing that point, having said that, as previous posters have said, the business in now under serious pressure to produce some positive news flow which goes beyond just "we have made good progress with clinical trials" |
I've learned never to average down on your losers, but average up on your winners. If institutions are dumping this, the only way is down. |
They need some good news on some of their more mature portfolio companies to try and change this poor sentiment. Hopefully we will hear more news on Autolus soon. Trading at a big discount to NAV and holding a lot of cash. I have done the dreaded thing and averaged down. |
Yeh gotta be institutions dumping now, wonder if Blackrock have had enough. |
EPIC currently describes the share price :( |
Can somebody please tell me how Marin Murphy is still in a job, he has destroyed shareholder value. |
Yes, very disappointing. At least they got £326m upfront, so the original decision to sell was a good call. The £54.5m write-off of deferred consideration is equivalent to 8.1p per share, so net asset value is now 176.5p based on the latest quarterly update, of which over 51% is in cash. Discount to asset value is now 32%, so still looking very cheap but this is poor for sentiment and to be honest they need some good news to emerge from their drug portfolio to change that. |
Oh dear, not good news, I'll hold off buying here. Blackrock must be losing tons on this. |
Ok thx, yeh i think they will recover, checking on shareholders, Blackrock bought a huge stake in these, so we'll see. |
Hugely out of favour and ignored, as you will know by being the first post since your exit one in March! While I made a lot of money from this by virtue of having them from BACIT at 100p launch and exiting average 248, and by having far more of them than was sensible, I did buy 10% of the original holding back in the mid 160's, so long and wrong on those. They are far below nav and unloved but I think there will be better days ahead when the sector turns, which might be helped once we get a turn in the interest rate cycle, as higher rates have been a big headwind for the sector. |
Checking back on this dog, might be tempted to nibble back in here, seems bio still out of favour. |
I got out of this last week, going nowere. |
Lets hope not. Just bought some. trading at a decent discount with lots of cash. They have a decent track record. Just need sentiment to change towards Biotechs. There must be a persistent seller around at the moment. Lets hope they are done soon. |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
